Atherosclerosis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Atherosclerosis – Pipeline Review, H1 2020’, provides an overview of the Atherosclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atherosclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Atherosclerosis

– The report reviews pipeline therapeutics for Atherosclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Atherosclerosis therapeutics and enlists all their major and minor projects

– The report assesses Atherosclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Atherosclerosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Atherosclerosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

13therapeutics Inc

Abcentra LLC

ABIONYX Pharma SA

AdaptVac ApS

AFFiRiS AG

Allysta Pharmaceuticals Inc

Amgen Inc

Annexin Pharmaceuticals AB

AptaBio Therapeutics Inc

Artery Therapeutics Inc

Asdera LLC

AstraZeneca Plc

Athera Biotechnologies AB

Auxagen Inc

Band Therapeutics LLC

BBN Cardio Therapeutics

Boehringer Ingelheim International GmbH

Centeer BioTherapeutics Ltd Co

CohBar Inc

Corbus Pharmaceuticals Inc

General Regeneratives Shanghai Ltd

GenKyoTex SA

Grindeks AS

Innolife Co Ltd

Inotrem SA

Inspyr Therapeutics Inc

Iproteos SL

Jenrin Discovery Inc

Kaleido Biosciences Inc

KineMed Inc

Kowa Co Ltd

LG Chem Ltd

LipimetiX Development Inc

MetiMedi Pharmaceuticals Co Ltd

Mperia Therapeutics Inc

Novartis AG

NuSirt Biopharma Inc

Omeros Corp

Pharmahungary Group

Regeneron Pharmaceuticals Inc

Repair Biotechnologies Inc

Riparian Pharmaceuticals Inc

Sansho Co Ltd

Serene LLC

Shin Poong Pharm Co Ltd

Signablok Inc

Tiara Pharmaceuticals Inc

Underdog Pharmaceuticals Inc

Vascular Biogenics Ltd

VasThera Research Institute

Vaxil Bio Therapeutics Ltd

Vicore Pharma AB

Wooridul Pharmaceutical Ltd

XBiotech Inc

Table of Contents

Table of Contents

Introduction

Atherosclerosis - Overview

Atherosclerosis - Therapeutics Development

Atherosclerosis - Therapeutics Assessment

Atherosclerosis - Companies Involved in Therapeutics Development

Atherosclerosis - Drug Profiles

Atherosclerosis - Dormant Projects

Atherosclerosis - Discontinued Products

Atherosclerosis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Atherosclerosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Atherosclerosis – Pipeline by 13therapeutics Inc, H1 2020

Atherosclerosis – Pipeline by Abcentra LLC, H1 2020

Atherosclerosis – Pipeline by ABIONYX Pharma SA, H1 2020

Atherosclerosis – Pipeline by AdaptVac ApS, H1 2020

Atherosclerosis – Pipeline by AFFiRiS AG, H1 2020

Atherosclerosis – Pipeline by Allysta Pharmaceuticals Inc, H1 2020

Atherosclerosis – Pipeline by Amgen Inc, H1 2020

Atherosclerosis – Pipeline by Annexin Pharmaceuticals AB, H1 2020

Atherosclerosis – Pipeline by AptaBio Therapeutics Inc, H1 2020

Atherosclerosis – Pipeline by Artery Therapeutics Inc, H1 2020

Atherosclerosis – Pipeline by Asdera LLC, H1 2020

Atherosclerosis – Pipeline by AstraZeneca Plc, H1 2020

Atherosclerosis – Pipeline by Athera Biotechnologies AB, H1 2020

Atherosclerosis – Pipeline by Auxagen Inc, H1 2020

Atherosclerosis – Pipeline by Band Therapeutics LLC, H1 2020

Atherosclerosis – Pipeline by BBN Cardio Therapeutics, H1 2020

Atherosclerosis – Pipeline by Boehringer Ingelheim International GmbH, H1 2020

Atherosclerosis – Pipeline by Centeer BioTherapeutics Ltd Co, H1 2020

Atherosclerosis – Pipeline by CohBar Inc, H1 2020

Atherosclerosis – Pipeline by Corbus Pharmaceuticals Inc, H1 2020

Atherosclerosis – Pipeline by General Regeneratives Shanghai Ltd, H1 2020

Atherosclerosis – Pipeline by GenKyoTex SA, H1 2020

Atherosclerosis – Pipeline by Grindeks AS, H1 2020

Atherosclerosis – Pipeline by Innolife Co Ltd, H1 2020

Atherosclerosis – Pipeline by Inotrem SA, H1 2020

Atherosclerosis – Pipeline by Inspyr Therapeutics Inc, H1 2020

Atherosclerosis – Pipeline by Iproteos SL, H1 2020

Atherosclerosis – Pipeline by Jenrin Discovery Inc, H1 2020

Atherosclerosis – Pipeline by Kaleido Biosciences Inc, H1 2020

Atherosclerosis – Pipeline by KineMed Inc, H1 2020

Atherosclerosis – Pipeline by Kowa Co Ltd, H1 2020

Atherosclerosis – Pipeline by LG Chem Ltd, H1 2020

Atherosclerosis – Pipeline by LipimetiX Development Inc, H1 2020

Atherosclerosis – Pipeline by MetiMedi Pharmaceuticals Co Ltd, H1 2020

Atherosclerosis – Pipeline by Mperia Therapeutics Inc, H1 2020

Atherosclerosis – Pipeline by Novartis AG, H1 2020

Atherosclerosis – Pipeline by NuSirt Biopharma Inc, H1 2020

Atherosclerosis – Pipeline by Omeros Corp, H1 2020

Atherosclerosis – Pipeline by Pharmahungary Group, H1 2020

Atherosclerosis – Pipeline by Regeneron Pharmaceuticals Inc, H1 2020

Atherosclerosis – Pipeline by Repair Biotechnologies Inc, H1 2020

Atherosclerosis – Pipeline by Riparian Pharmaceuticals Inc, H1 2020

Atherosclerosis – Pipeline by Sansho Co Ltd, H1 2020

Atherosclerosis – Pipeline by Serene LLC, H1 2020

Atherosclerosis – Pipeline by Shin Poong Pharm Co Ltd, H1 2020

Atherosclerosis – Pipeline by Signablok Inc, H1 2020

Atherosclerosis – Pipeline by Tiara Pharmaceuticals Inc, H1 2020

Atherosclerosis – Pipeline by Underdog Pharmaceuticals Inc, H1 2020

Atherosclerosis – Pipeline by Vascular Biogenics Ltd, H1 2020

Atherosclerosis – Pipeline by VasThera Research Institute, H1 2020

Atherosclerosis – Pipeline by Vaxil Bio Therapeutics Ltd, H1 2020

Atherosclerosis – Pipeline by Vicore Pharma AB, H1 2020

Atherosclerosis – Pipeline by Wooridul Pharmaceutical Ltd, H1 2020

Atherosclerosis – Pipeline by XBiotech Inc, H1 2020

Atherosclerosis – Dormant Projects, H1 2020

Atherosclerosis – Dormant Projects, H1 2020 (Contd..1), H1 2020

Atherosclerosis – Dormant Projects, H1 2020 (Contd..2), H1 2020

Atherosclerosis – Dormant Projects, H1 2020 (Contd..3), H1 2020

Atherosclerosis – Dormant Projects, H1 2020 (Contd..4), H1 2020

Atherosclerosis – Dormant Projects, H1 2020 (Contd..5), H1 2020

Atherosclerosis – Dormant Projects, H1 2020 (Contd..6), H1 2020

Atherosclerosis – Dormant Projects, H1 2020 (Contd..7), H1 2020

Atherosclerosis – Dormant Projects, H1 2020 (Contd..8), H1 2020

Atherosclerosis – Discontinued Products, H1 2020

Atherosclerosis – Discontinued Products, H1 2020 (Contd..1), H1 2020

Atherosclerosis – Discontinued Products, H1 2020 (Contd..2), H1 2020

List of Figures

List of Figures

Number of Products under Development for Atherosclerosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports